Literature DB >> 33633954

Identification of a novel large deletion of the mitochondrial DNA in an infant with Pearson syndrome: a case report.

Rui Liu1, Gui-Ling Mo2, Yuan-Zong Song1.   

Abstract

Pearson syndrome (PS), also known as Pearson marrow-pancreas syndrome, is a rare, multi-systemic disorder caused by large-scale deletion of mitochondrial DNA (mtDNA) ranging from 2.3 kb to 9 kb, with 4,977 bp in length as the most common variant. This paper reported a novel mtDNA deletion of 4,734 bp in size, spanning from nucleotide 11,220 to 15,953. The infant suffered from chronic hepatomegaly, liver dysfunction, anemia and lactic acidosis over 1 year. Evidences of any infections were negative. Bone marrow aspiration and whole exome sequencing covering nearly 20,000 nucleus genes were performed when aged 3.3 and 6 months, respectively, but no genetic cause was identified. However, at his age 13 months, multiplex ligation-dependent probe amplification assay of the mtDNA in the patient detected a large deletion of 4,734 bp in size spanning the mitochondrial genes MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT which were functionally crucial for the intact oxidative phosphorylation pathway and adenosine triphosphate production, and PS was thus definitely diagnosed. This large deletion was negative in his parents and elder brother. Oral ursodeoxycholic acid, fat-soluble vitamins and blood transfusions were administrated, his clinical and laboratory presentations remained stable so far, but the long-term prognosis needed to be followed up. These findings enriched the variant spectrum of mtDNA, and demonstrated the importance of considering mitochondrial disorder in patient with intractable anemia, liver dysfunction and lactic acidosis as well as the significance of appropriate choosing of relevant genetic tools in the etiology diagnosis of such patients. 2021 Translational Pediatrics. All rights reserved.

Entities:  

Keywords:  Infant; Pearson syndrome (PS); case report; mitochondrial DNA (mtDNA); variant

Year:  2021        PMID: 33633954      PMCID: PMC7882279          DOI: 10.21037/tp-20-138

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


Introduction

Pearson syndrome (PS) first described by Pearson and his colleagues in 1979 (1), is a rare, multi-systemic mitochondrial disorder that occurs in early infancy, featured by vacuolated marrow precursors and exocrine pancreatic dysfunction (2). Other clinical presentations include lactic acidosis, insulin-dependent diabetes mellitus, liver dysfunction, renal tubular dysfunction, failure to thrive, and muscular and neurologic impairment (3-6). PS is caused by single large-scale mitochondrial DNA (mtDNA) deletions (SLSMDs) ranging from 2.3 to 9 kb, with 4,977 bp in length as the most common variant (7). Due to one or multiple mtDNA deletions of varying size, location and proportion, mitochondrial oxidative phosphorylation (OXPHO) could be impaired, resulting in reduced energy production (8). The diagnosis of PS syndrome depends on mtDNA analysis (7). To the best of our knowledge, the reported PS cases were rather limited in number, and up to date, about 109 PS patients were reported, including 52 ones with infant onset (6,9-12). Here, we reported a rare and challenging case with atypical clinical presentation soon after birth, which was definitely diagnosed by mtDNA analysis. These findings also enriched the variant spectrum of mtDNA. In combination with the patient's clinical manifestations, early etiology exploration was important for the diagnosis and management of such patients. We presented the following case in accordance with the CARE reporting checklist (13). Available at http://dx.doi.org/10.21037/tp-20-138.

Case presentation

A 13-month-old male patient was referred to our clinic due to hepatomegaly, abnormal liver function and anemia discovered over 1 year. At the age of 18 hours, he was referred to neonatal intensive care unit due to jaundice and tachypnea soon after birth. The liver was normal in size and texture, but the serum levels of total bile acids, total bilirubin, aspartate transaminase and lactate were all elevated, along with a hemoglobin level of 91 g/L (). The diagnoses of moderate anemia, liver dysfunction and lactic acidosis were thus made while phototherapy and blood transfusion were given. As a result, jaundice and anemia were alleviated, but abnormal liver function and lactic acidosis remained refractory. Since being discharged at age 1.5 months, he was referred to different hospitals due to persisted abnormal liver function, intractable anemia and lactic acidosis despite the usage of oral ursodeoxycholic acid (5 mg/kg, q12h), coenzyme Q (10 mg, qd), carnitine (50 mg/kg, qd) and vitamin D (400 IU, qd). The patient became transfusion dependent for red blood cells and he developed transient neutropenia in the first 2 months of life (minimum 0.83×109/L). Evidences of any infections were negative. Bone marrow aspiration (BMA) and whole exome sequencing (WES) covering nearly 20,000 nucleus genes were performed when aged 3.3 and 6 months, respectively, but no genetic cause was identified.
Table 1

Laboratory indices over time in the patient

Indices (reference range)Ages
1 D4 D1 M 3 D1 M 27 D2 M 6 D2 M 11 D8 M 23 D10 M 24 D13 M
ALT (5–40 U/L)2442106131107
AST (8–40 U/L)6011910712092112105180
GGT (7–50 U/L)15775924894251319352
TBA (0–10 μmol/L)91.033.7282.0267.913.419.998.1
TBIL (2–17 μmol/L)216.9260.770.6232.5163.9185.09.617.7
DBIL (0–7 μmol/L)22.324.2165.7120.6123.33.78.8
IBIL (2–13.7 μmol/L)238.446.466.862.65.98.9
RBC [(4–4.5) ×1012/L]3.352.432.592.263.572.802.722.88
HGB (105–145 g/L)9112275796610410887108
Lactate (0.9–1.7 mmol/L)7.510.219.218.28.53.26.5

D, day; M, month; ALT, alanine transaminase; AST, aspartate transaminase; TBA, total bile acids; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; RBC, red blood cells; HGB, hemoglobin.

D, day; M, month; ALT, alanine transaminase; AST, aspartate transaminase; TBA, total bile acids; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; RBC, red blood cells; HGB, hemoglobin. As the second product of a non-consanguineous couple, the child was delivered spontaneously at the gestational age of 39 weeks after an uneventful pregnancy, with a birth weight of 3.2 kg, body length 51 cm and head circumference 34 cm. The parents were healthy, and there was no family history of any genetic or metabolic disorders. Physical examination at referral revealed a body weight of 7.4 kg [<−3 standard deviation (SD)], height 74.8 cm (<−3 SD), and head circumference 42.9 cm (<−2 SD). No cutaneous and scleral pallor or jaundice could be observed. The lungs were clear. No murmurs or abnormal heart sounds were heard. There was no abdominal distention, but a liver 3.5 cm below the right subcostal margin with medium texture was palpable. The spleen was not enlarged. Physiological reflexes were normal and no pathological reflexes could be found on nervous system examination. The extremities were warm, and the distal perfusion was excellent. Biochemistry tests revealed abnormal liver function and lactic acidosis (). Multiplex ligation-dependent probe amplification (MLPA) assay of the mtDNA detected a large deletion involving 9 mitochondrial genes including MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT in the patient (), which was negative in his parents and elder brother. Further next-generation sequencing (NGS) test of the mitochondrial genome uncovered a mtDNA deletion of 4,734 bp (from nucleotide 11,220 to 15,953), confirming the MLPA findings. was the timeline of the relevant information about the patient.
Figure 1

MLPA assay results of the patient. The horizontal axis represented the probe positions, while the vertical, the fluorescence signal ratio of subject sample/normal control which was represented as mean ± SD in this figure. On the top were the probe labels. The red and the blue curves represented the normal upper and lower limits of the ratios, respectively. The green boxes indicated the reliability of the experiments. The 9 genes MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT (dots in red on the right) displayed ratios ranging from 0.25 to 0.75, indicating a large deletion. The remaining 23 mtDNA genes (dots in black) exhibited normal ratios. MLPA, multiplex ligation-dependent probe amplification; SD, standard deviation.

Figure 2

Timeline of the patient.

MLPA assay results of the patient. The horizontal axis represented the probe positions, while the vertical, the fluorescence signal ratio of subject sample/normal control which was represented as mean ± SD in this figure. On the top were the probe labels. The red and the blue curves represented the normal upper and lower limits of the ratios, respectively. The green boxes indicated the reliability of the experiments. The 9 genes MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT (dots in red on the right) displayed ratios ranging from 0.25 to 0.75, indicating a large deletion. The remaining 23 mtDNA genes (dots in black) exhibited normal ratios. MLPA, multiplex ligation-dependent probe amplification; SD, standard deviation. Timeline of the patient. PS was thus definitely diagnosed, and oral vitamin D (400 IU, qd) was suggested to be remained. He had normal developmental milestones, his physical, cognitive, social, and language development have remained typical for age. His condition remained stable so far, but he still suffered from mild anemia, abnormal liver function and lactic acidosis, and clinic follow up was underway. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the parents.

Discussion

The diagnosis of PS in newborns is often difficult, because its clinical features may overlap with infectious, neuromuscular, hematological, metabolic, or digestive diseases (8,14). Hepatomegaly, liver dysfunction, anemia and lactic acidosis were chronic but non-pathognomonic presentations in this patient. Although a series of tests including WES analysis had been conducted, the etiology remained unclear until MLPA revealed the novel mtDNA deletion which was confirmed by NGS analysis. This child’s case enriched the mtDNA mutation spectrum and supported the complexity of the etiology exploration process as well as the significance of appropriate choosing of relevant analytic tools for genetic diseases. The genes ND4, ND5 and ND6 encoded subunits of complex I while CYB encoded a subunit of complex III in the mitochondrial respiratory chain (MRC) (15), and thus deletion in this patient affected MRC to produce adenosine triphosphate (ATP). The MRC impairment led to disruption of Krebs cycle and thus accumulation of pyruvate, which was converted to lactate, giving rise to his intractable lactic acidosis (16). Due to the mtDNA mutation, an erythroid maturation was defected (17), constituting an explanation for his prolonged anemia. Meanwhile, ATP shortage in the hepatocyte hampered the canalicular carrier proteins to transport bile components like bile acids and bilirubin, contributing to his hepatomegaly and liver dysfunction (18). There is no curative treatment for PS patients and therapy is primarily symptomatic. Blood transfusion and bicarbonate supplementation was required for management. And pancreatic enzyme replacement is needed for patients with malabsorption due to exocrine pancreatic dysfunction. The prognosis of PS patient was poor usually, and about 75% of them died before 5 years of age, with intractable metabolic acidosis, renal or hepatic failure and sepsis (7). Although stable in condition currently, the long-term outcome of our patient needs to be observed. This paper described the clinical and molecular presentations of a pediatric PS patient harboring a large mtDNA deletion. For the well understanding of the genetic and phenotypic features of this rare mitochondrial disorder, however, more PS patients need to be identified and characterized.

Conclusions

In conclusion, this paper reported an infant with PS caused by a novel mtDNA deletion of 4,734 bp. These findings enriched the variant spectrum of mtDNA, and demonstrated the importance of considering mitochondrial disorder in patient with intractable anemia, liver dysfunction and lactic acidosis as well as the significance of appropriate choosing of relevant genetic tools in the etiology diagnosis of such patients. The article’s supplementary files as
  18 in total

1.  Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy.

Authors:  A Rötig; V Cormier; S Blanche; J P Bonnefont; F Ledeist; N Romero; J Schmitz; P Rustin; A Fischer; J M Saudubray
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 2.  Pearson syndrome in the neonatal period: two case reports and review of the literature.

Authors:  Elena Maria Manea; Guy Leverger; Francoise Bellmann; Popp Alina Stanescu; Adam Mircea; Anne-Sophie Lèbre; Agnes Rötig; Arnold Munnich
Journal:  J Pediatr Hematol Oncol       Date:  2009-12       Impact factor: 1.289

3.  Endothelial dysfunction in a child with Pearson marrow-pancreas syndrome managed with Descemet stripping automated endothelial keratoplasty using a suture pull-through technique.

Authors:  Raghav Vadhul; Caroline S Halbach; Raymond G Areaux; Susan Berry; Joshua H Hou
Journal:  Digit J Ophthalmol       Date:  2019-11-17

4.  A novel mitochondrial DNA deletion in a patient with Pearson syndrome and neonatal diabetes mellitus provides insight into disease etiology, severity and progression.

Authors:  Xin-Yu Chen; Si-Yu Zhao; Yan Wang; Dong Wang; Chang-Hu Dong; Ying Yang; Zhi-Hua Wang; Yuan-Ming Wu
Journal:  Mitochondrial DNA A DNA Mapp Seq Anal       Date:  2015-05-27       Impact factor: 1.514

5.  CARE guidelines for case reports: explanation and elaboration document.

Authors:  David S Riley; Melissa S Barber; Gunver S Kienle; Jeffrey K Aronson; Tido von Schoen-Angerer; Peter Tugwell; Helmut Kiene; Mark Helfand; Douglas G Altman; Harold Sox; Paul G Werthmann; David Moher; Richard A Rison; Larissa Shamseer; Christian A Koch; Gordon H Sun; Patrick Hanaway; Nancy L Sudak; Marietta Kaszkin-Bettag; James E Carpenter; Joel J Gagnier
Journal:  J Clin Epidemiol       Date:  2017-05-18       Impact factor: 6.437

6.  Pearson marrow-pancreas syndrome with cardiac conduction abnormality necessitating prophylactic pacemaker implantation.

Authors:  Mats Steffi Jennifer; Daniel Cortez
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-09-01       Impact factor: 1.468

Review 7.  Bone marrow features in Pearson syndrome with neonatal onset: A case report and review of the literature.

Authors:  Elisa Tadiotto; Evelina Maines; Daniela Degani; Rita Balter; Andrea Bordugo; Simone Cesaro
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

Review 8.  Pearson syndrome.

Authors:  Piero Farruggia; Floriana Di Marco; Carlo Dufour
Journal:  Expert Rev Hematol       Date:  2018-01-23       Impact factor: 2.929

9.  Spectrum of mitochondrial DNA rearrangements in the Pearson marrow-pancreas syndrome.

Authors:  A Rötig; T Bourgeron; D Chretien; P Rustin; A Munnich
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

10.  Tubulopathy and pancytopaenia with normal pancreatic function: a variant of Pearson syndrome.

Authors:  Agnès Atale; Patrizia Bonneau-Amati; Agnès Rötig; Alain Fischer; Stéphanie Perez-Martin; Pascale de Lonlay; Patrick Niaudet; L De Parscau; C Mousson; C Thauvin-Robinet; A Munnich; F Huet; L Faivre
Journal:  Eur J Med Genet       Date:  2008-11-05       Impact factor: 2.708

View more
  1 in total

1.  Comprehensive clinical and genetic work-up of patients carrying single mtDNA deletions is warranted.

Authors:  Josef Finsterer
Journal:  Transl Pediatr       Date:  2021-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.